发明名称 |
Method for treating prostate cancer |
摘要 |
The invention provides a method for treating prostate cancer in a subject comprising administering to the subject an effective amount of a selective inhibitor of one or more of CDK8 and CDK19. In some embodiments the inhibitor inhibits CDK19. In some embodiments, the inhibitor inhibits CDK8 at a Kd of lower than 200 nM and/or inhibits CDK19 at a Kd of lower than 100 nM. In some embodiments, the prostate cancer is androgen independent. In some embodiments, the prostate cancer is androgen independent due to one or more of androgen receptor gene amplification, androgen receptor gene mutation, ligand-independent transactivation of androgen receptor and activation of intracellular androgen synthesis. In some embodiments, the inhibitor inhibits increased activity of NF-κB. In some embodiments, the inhibitor does not inhibit increased basal levels of NF-κB. In some embodiments, inhibition of one or more genes by AR is not inhibited. |
申请公布号 |
US9636342(B2) |
申请公布日期 |
2017.05.02 |
申请号 |
US201314439127 |
申请日期 |
2013.11.01 |
申请人 |
University of South Carolina |
发明人 |
Chen Mengqian;Roninson Igor |
分类号 |
A61K31/517;A61K31/5377 |
主分类号 |
A61K31/517 |
代理机构 |
Verrill Dana LLP |
代理人 |
Keown Wayne A.;Verrill Dana LLP |
主权项 |
1. A method for treating prostate cancer in a subject comprising administering to the subject an effective amount of a selective inhibitor of one or more of CDK8 and CDK19, wherein the prostate cancer is androgen independent and wherein said inhibitor inhibits increased activity of NF-κB. |
地址 |
Columbia SC US |